Risks and prevention of severe RS virus infection among children with immunodeficiency and Down's syndrome.

Abstract

By the age of two years, almost all infants are infected with the Respiratory syncytial virus (RSV). One of the main causes of hospitalizations for bronchiolitis and pneumonia at this age is RSV infection. In addition to well-known risks for severe RSV disease, such as prematurity, bronchopulmonary dysplasia and congenital heart disease, immunodeficiencies, chromosomal abnormalities such as Down's syndrome or neuromuscular diseases have also been identified as risks. While the medical needs for RSV prevention in these risk groups are high, clinical evidence to support this is limited. Palivizumab was recently approved in Japan for prophylaxis in children with immunodeficiency or Down's syndrome. A clinical guidance protocol for the prevention of RSV infection using Palivizumab in these risk groups is provided here on the basis of a review of the available literature and on expert opinion. Thus, the present article reviews the published literature related to RSV infections in infants and children with immunodeficiencies or Down's syndrome in order to outline the risks, pathology and physiology of severe RSV disease in these patient groups. The purpose of this article is to facilitate understanding of the medical scientific bases for the clinical guidance.

• Authors: Masaaki Mori, Tomohiro Morio, Shuichi Ito, Akira Morimoto, Setsuo Ota, Koichi Mizuta, Tsutomu Iwata, Toshiro Hara, Tsutomu Saji
• Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (J Infect Chemother) Vol. 20 Issue 8 Pg. 455-9 (Aug 2014) ISSN: 1437-7780 [Electronic] Netherlands
• PMID: 24929631 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2014 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Chemical References

• Antibodies, Monoclonal, Humanized
• Antiviral Agents
• Palivizumab

Topics

• Antibodies, Monoclonal, Humanized (therapeutic use)
• Antiviral Agents (therapeutic use)
• Child
• Child, Preschool
• Down Syndrome (complications)
• Humans
• Immunocompromised Host
• Immunologic Deficiency Syndromes (complications)
• Infant
• Infant, Newborn
• Infection Control
• Palivizumab
• Respiratory Syncytial Virus Infections (complications, drug therapy, prevention & control)
• Risk Factors